NCT06673368 is a Phase 2 clinical trial of NRCT-101SR, NRCT-202XR in ADHD, sponsored by Neurocentria, Inc..

Who is sponsoring NCT06673368?

NCT06673368 is sponsored by Neurocentria, Inc..

What drugs are being tested in NCT06673368?

Interventions in NCT06673368: NRCT-101SR, NRCT-202XR.

Is NCT06673368 still recruiting?

NCT06673368 is currently terminated. Last updated 15 January 2026.

Last reviewed 2026-01-15 · How we verify

NCT06673368

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Phase 2 Randomized Double-Blind, Parallel, Adaptive-Design, Clinical Trial to Evaluate the Safety and Efficacy of NRCT-101SR With NRCT-202XR Compared to NRCT-202XR Alone in Subjects With Attention-Deficit/Hyperactivity Disorder

Terminated Phase 2 Last updated 15 January 2026

What this trial tests

Phase 2 trial testing NRCT-101SR, NRCT-202XR in ADHD in 2 participants. Terminated before completion.

Timeline

25 February 2025

Primary endpoint
15 July 2025

15 July 2025

Quick facts

Lead sponsor	Neurocentria, Inc.
Phase	Phase 2
Status	Terminated
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	2
Start date	25 February 2025
Primary completion	15 July 2025
Estimated completion	15 July 2025
Sites	5 locations across United States

Drugs / interventions tested

NRCT-101SR, NRCT-202XR — full drug profile →

Conditions studied

ADHD — all drugs for ADHD →

Sponsor

Neurocentria, Inc. — full company profile →

Who can join

Adults 13 to 17, any sex, with ADHD. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A combination therapy of NRCT-101 with NRCT-202 is being developed for patients with ADHD.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for ADHD

Currently open trials in the same condition.

NCT07314333 — A Trial to Assess How Centanafadine Interacts With Stimulants in the Body · Phase 1 · recruiting
NCT07262853 — Dual Executive Function Training Package · NA · recruiting
NCT07291453 — Loving Habits: A Feasibility Study of a Support Program for Building New Parent-child Behavioral Habits · NA · recruiting
NCT07281092 — Comparative Efficacy of Organizational Skills Training (OST) and Mindfulness-Based Intervention (MBI) · NA · recruiting
NCT07219810 — Accelerated iTBS Targeting of Working Memory Versus Inhibitory Control in Adolescent ADHD · NA · recruiting

Other Neurocentria, Inc. trials

Trials by the same sponsor.

NCT06215144 — Study to Evaluate NRCT-101SR in Pediatric Subjects With ADHD · Phase 2, PHASE3 · terminated
NCT05683249 — Study to Evaluate NRCT-101SR in Adult Attention Deficit Hyperactivity Disorder (ADHD) · Phase 2, PHASE3 · completed
NCT03601169 — Comparison of MMFS Dosages in Older Adults · Phase 2 · completed
NCT03531684 — Efficacy and Safety of MMFS in Early AD · Phase 2 · completed

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06673368 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Neurocentria, Inc.
Last refreshed: 15 January 2026

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06673368.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing